0000950170-23-066532.txt : 20231128 0000950170-23-066532.hdr.sgml : 20231128 20231128203246 ACCESSION NUMBER: 0000950170-23-066532 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231124 FILED AS OF DATE: 20231128 DATE AS OF CHANGE: 20231128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Encrantz Staffan CENTRAL INDEX KEY: 0001870875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40587 FILM NUMBER: 231448174 MAIL ADDRESS: STREET 1: C/O SIGHT SCIENCES, INC. STREET 2: 4040 CAMPBELL AVENUE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sight Sciences, Inc. CENTRAL INDEX KEY: 0001531177 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 800625749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 SAND HILL ROAD STREET 2: BUILDING 3, SUITE 105 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: (415) 889-0550 MAIL ADDRESS: STREET 1: 3000 SAND HILL ROAD STREET 2: BUILDING 3, SUITE 105 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2023-11-24 0001531177 Sight Sciences, Inc. SGHT 0001870875 Encrantz Staffan C/O SIGHT SCIENCES, INC. 4040 CAMPBELL AVE., SUITE 100 MENLO PARK CA 94025 true false true false false Common Stock 2023-11-24 4 P false 21855 3.0852 A 368150 D Common Stock 2023-11-27 4 P false 246331 3.3124 A 614481 D Common Stock 2023-11-28 4 P false 253669 3.4578 A 868150 D Common Stock 1184258 I See footnote Common Stock 4022118 I See footnote Reflects the weighted average price at which these shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $2.96 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $3.035 to $3.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $3.275 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program, which are subject to vesting as previously reported. Each RSU represents a contingent right to receive one share of Common Stock. These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. /s/ Jeremy Hayden, Attorney-in-Fact for Staffan Encrantz 2023-11-28